Neuro Spectrum Insights, Inc. is a medical device company focused on commercializing a patented software solution named GyriCalc™, designed to assist in diagnosing autism by analyzing MRI images for structural markers. Although GyriCalc has received FDA 510(k) marketing clearance, it has not yet received FDA clearance for diagnostic use. The company currently does not generate revenue and seeks to launch GyriCalc in U.S. and Canadian markets, emphasizing strategic partnerships and reimbursement mechanisms for market penetration.
Neuro Spectrum Insights, Inc. does not currently generate revenue as it is in the commercialization phase of its product, GyriCalc. The company aims to establish market access strategies focusing on partnerships and government discussions for reimbursement.
Proceeds from the offering will be used to fund working capital and general corporate purposes, which may include product development, marketing, and other operational needs.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
Neuro Spectrum Insights, Inc. is headquartered in United States and incorporated in DE. It is classified under Surgical & Medical Instruments & Apparatus.
Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Jul 31, 2026.
View the original filing on SEC EDGAR →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy